AAV & Ex Vivo Gene Lentiviral Therapy
Source: Cytiva
Douglas Sanders, Ph.D., VP Head of Translational Medicine at AVROBIO provides detailed examples of the diseases that are a better fit for AAV or ex vivo lentiviral gene therapy and why.
VIEW THE VIRTUAL EVENT!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Cytiva
This website uses cookies to ensure you get the best experience on our website. Learn more